Frates James M sold 12,800 shares of Amylyx Pharmaceuticals, Inc. at $30.32 for −$388k on Nov 10, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Financial Officer
Chief Financial Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$388,107.52Shares × reported price
Shares traded
12,800Common Stock
Price per share
$30.32Reported price. Read footnotes for ranges.
% of reported position traded
5.05%This security and ownership context
Holdings after
240,825Direct
Trade date
Nov 10, 2026Sell
Filed
Nov 12, 2026, 4:00 PM ET2-day reporting delay
Accession
0001193125-26-458247Code S · Transaction 398630
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 253,625 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell7,700$29.39−$226,292.99Trade 398627
Nov 9, 2026Sell12,300$30.11−$370,359.15Trade 398628
Nov 10, 2026Sell7,200$30.97−$222,982.56Trade 398631
Nov 9, 2026Option exercise20,000$6.88$137,600Trade 398626
Nov 10, 2026Option exercise20,000$6.88$137,600Trade 398629
Nov 9, 2026Option exercise20,000$0.00$0Trade 398632
Nov 10, 2026Option exercise20,000$0.00$0Trade 398633
8 transaction rows in this filing. Joint filers share the same rows.

AMLX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
AMLX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +1.9%1w ago +5.7%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 10, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.81 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.82 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.86 to $30.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.905 to $31.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F6: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. F7: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. F8: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. F9: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. F10: This option is fully vested and exercisable.